January 20, 2016
German Biofrontera leaving London Stock Exchange
Biofrontera, the biopharmaceutical company focusing on sun-induced skin cancer, has decided to cancel the admission of its ordinary shares to trading…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
January 18, 2016
Eurostars grant awarded to international consortium including Abzena company, Antitope, for development of novel treatment for clotting disorders
Eurostars grant awarded to international consortium including Abzena company, Antitope, for development of novel treatment for clotting disorders
January 15, 2016
French drug trial disaster leaves one brain dead, five injured
One person has been left brain dead and five others have been hospitalised after taking part in a clinical trial in France of an experimental drug made by Portuguese drug company Bial, French Health Minister Marisol Touraine said on Friday.
January 15, 2016
Premaitha Health CEO: “NSC recommendation a key milestone for prenatal testing in UK”
Premaitha Health PLC welcomes the UK National Screening Committee’s (NSC) recommendation to routinely offer NIPT testing on the NHS to…
January 12, 2016
Drugmaker Shire to buy Baxalta for $32 billion after six-month pursuit
Drugmaker Shire Plc clinched its six-month pursuit of Baxalta International Inc on Monday with an agreed $32 billion (22 billion pound) cash and stock offer, catapulting it to a leading position in treating rare diseases.
January 11, 2016
Sanofi and Warp Drive Bio extend collaboration
Sanofi and Warp Drive Bio have extended and reshaped their existing collaboration utilizing Warp Drive’s proprietary SMART(TM) (Small Molecule Assisted…
January 7, 2016
New year-round treatment option for daylight-PDT for use in dermatological practices
SwissRed AG, Murten, has, in collaboration with Biofrontera, received the European CE marking for its IndoorLux illumination system for treatment…
January 6, 2016
LivaNova: “FDA’s Warning Letter can be resolved without material impact on financial results”
LivaNova said that FDA’s Warning Letter can be resolved without a material impact on financial results.
January 6, 2016
Glenmark’s generic Multaq tablets wait for final FDA approval after tentative
Glenmark Pharmaceuticals Inc., has been granted tentative approval by the USFDA for its Dronedarone Tablets, 400 mg, the generic version…
January 5, 2016
Glenmark confirms reaching agreement with Roche over patent disputes
Glenmark confirms reaching agreement with Roche over patent disputes